Compare DoorDash Inc (DASH) vs Danaher Corporation (DHR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DoorDash Inc vs Danaher Corporation — how do they compare? DoorDash Inc trades at $191.73 (market cap $83.07B), while Danaher Corporation trades at $218.41 (market cap $152.87B). The key difference: Danaher Corporation is the larger of the two by market cap, and Danaher Corporation pays a 0.74% dividend while DoorDash Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold DoorDash Inc for 59 Days and Danaher Corporation for 69 Days on average.
| DASH | DHR | |
|---|---|---|
Market Cap | $83.07B | $152.87B |
Volume | 3,242,567 | 5,228,698 |
Sector | Media | Health |
52-Week High | $275.44 | $242.05 |
52-Week Low | $146.60 | $161.91 |
Typical Hold Time | 59 Days | 69 Days |
Enterprise Value | $81.03B | $175.08B |
Dividend Yield | — | 0.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DoorDash (DASH) trades at $191.24, down 1.23% on the day, with a bullish technical signal supported by moving averages. The company shows strong revenue growth, reaching $13.72 billion in 2025, and achieved profitability with a net income margin of 6.81%. Recent developments include the launch of AI-powered text ordering and drone delivery expansion, signaling innovation in its core delivery business.
The outlook is positive with a consensus price target of $255.80, though high valuation multiples and mixed quarterly earnings misses pose risks. Investor sentiment is bolstered by analyst optimism, but regulatory scrutiny and competitive pressures remain key concerns for sustained growth.
Danaher (DHR) trades at $218.49, up 1.36% on the day, with a bullish technical signal and consistent earnings beats in recent quarters. The stock shows strong profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst consensus is strongly bullish with a $230.31 price target, supported by institutional buying activity and a recent dividend announcement.
The outlook for DHR is positive, driven by earnings momentum and institutional confidence, but risks include elevated valuation multiples and competitive pressures in the healthcare sector. Investors should weigh the strong analyst support against potential margin compression and macroeconomic headwinds affecting capital spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DoorDash Inc
Founded in 2013 and headquartered in San Francisco, DoorDash is an online food order demand aggregator. Consumers can use its app to order food on-demand for pickup or delivery from merchants mainly in the U.S. The firm provides a marketplace for the merchants to create a presence online, market their offerings, and meet demand by making the offerings available for pickup or delivery. The firm provides similar service to businesses in addition to restaurants, such as grocery, retail, pet supplies, and flowers. At the end of 2020, DoorDash had over 450,000 merchants, 20 million consumers, and over 1 million dashers on its platform. In 2020, the firm generated $24.7 billion in gross order volume (up 207% year over year) and $2.9 billion in revenue (up 226%).
Read more on DASH →About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →
